Financial Data and Key Metrics Changes - The company reported revenue of $5.7 billion for Q4 2025, growing 4.8% organically year-over-year, exceeding expectations [14] - Full year revenue reached $20.6 billion, with organic growth of 3.5%, ahead of guidance [15] - Adjusted EBIT margin for 2025 was 15.3%, a decline of 100 basis points year-over-year, impacted by approximately $245 million in tariff expenses [16] - Adjusted EPS for 2025 was $4.59, growing 2.2%, with a tariff impact of $0.43 [16] - Free cash flow for Q4 was $916 million, up $105 million year-over-year, and $1.5 billion for the full year [15][22] Business Line Data and Key Metrics Changes - **Imaging**: Organic revenue grew 5.3% in Q4, driven by strong performance in EMEA and the U.S., particularly in nuclear medicine [17] - **Advanced Visualization Solutions**: Organic revenue increased 4.2% in Q4, supported by new product adoption [18] - **Patient Care Solutions**: Organic revenue declined 1.1% year-over-year due to a drop in life support solutions, but EBIT margin improved sequentially [19] - **Pharmaceutical Diagnostics**: Achieved organic sales growth of 12.7%, driven by global growth in contrast media [20] Market Data and Key Metrics Changes - Demand in the U.S. and EMEA remained strong, with a record backlog of $21.8 billion, growing $2 billion year-over-year [14] - The company secured multiple large agreements, including a significant collaboration with Sutter Health and a multi-year agreement with the Ministry of Health in Indonesia [10][11] Company Strategy and Development Direction - The company is focused on an innovation renaissance, emphasizing integrated solutions for complex and chronic diseases [4] - The strategic framework includes precision care, growth acceleration, and business optimization, with a strong emphasis on the Heartbeat business system to improve productivity and customer experience [11][12] - The planned acquisition of Intelerad is expected to enhance the company's cloud-first imaging ecosystem and drive recurring revenue [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver over $500 million in Flyrcado revenue by year-end 2028, viewing it as a billion-dollar opportunity in the long run [10] - The company anticipates organic revenue growth of 3%-4% for 2026, with a cautious outlook on China impacting overall guidance [22][23] - Management highlighted the importance of new product launches and regulatory approvals in driving future growth [30] Other Important Information - The company has made significant investments in innovation, totaling over $1.7 billion in 2025, to strengthen competitiveness and support growth [17] - The company is focused on expanding recurring revenue through service agreements and has seen positive trends in service growth [72] Q&A Session Summary Question: Can you provide more color on the 2% order growth and outlook for orders in 2026? - Management noted a robust book-to-bill ratio of 1.06x and a record backlog, indicating a solid order backdrop despite a challenging first quarter comparison [27][28] Question: What is the current state of Flyrcado and its adoption? - Management reported positive feedback from clinicians regarding Flyrcado's image quality and convenience, with consistent delivery rates improving [31][32] Question: How should we think about the assumptions for China and potential EPS upside? - Management took a cautious approach regarding China, anticipating a decline in 2026 but noting improvements in VBP win rates and a robust imaging funnel [40][41] Question: Can you elaborate on the pricing strategy for 2026? - Management indicated that while there are no significant price increases expected initially, new product launches may lead to better pricing opportunities later in the year [77] Question: What is the status of the Intelerad acquisition? - The acquisition is expected to close in the first half of the year and is anticipated to enhance the company's capabilities in cloud-enabled AI solutions [79][80]

Financial Data and Key Metrics Changes - The company reported revenue of $5.7 billion for Q4 2025, representing a 4.8% organic growth year-over-year, exceeding expectations [14] - For the full year 2025, revenue reached $20.6 billion, with organic growth of 3.5%, ahead of guidance [16] - Adjusted EBIT margin for Q4 was 16.7%, down 200 basis points due to tariff expenses and unfavorable mix [14] - Adjusted EPS for Q4 was $1.44, down 0.7%, but grew 11% when excluding tariff impacts [15] - Free cash flow for Q4 was $916 million, up $105 million year-over-year [15] Business Line Data and Key Metrics Changes - Pharmaceutical Diagnostics saw organic sales growth of 12.7%, driven by global growth in contrast media and pricing execution [20] - Imaging organic revenue grew 5.3% in Q4, with strong performance in EMEA and the US, particularly in nuclear medicine [17] - Advanced Visualization Solutions reported organic revenue growth of 4.2%, supported by new product adoption [18] - Patient Care Solutions experienced a 1.1% decline in organic revenue due to a drop in life support solutions, but EBIT margin improved sequentially [19] Market Data and Key Metrics Changes - Demand in the U.S. and EMEA remained strong, with a record backlog of $21.8 billion, up $2 billion year-over-year [14] - The company secured multiple large agreements, including a significant collaboration with Sutter Health and a multi-year agreement with the Ministry of Health in Indonesia [10][11] Company Strategy and Development Direction - The company is focused on an innovation renaissance, emphasizing integrated solutions for complex and chronic diseases [4] - The strategic framework includes precision care, growth acceleration, and business optimization, with a strong emphasis on the Heartbeat business system to drive productivity and customer experience [11][12] - The planned acquisition of Intelerad is expected to enhance the company's cloud-first imaging ecosystem and drive recurring revenue [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver over $500 million in Flyrcado revenue by year-end 2028, viewing it as a billion-dollar opportunity in the long run [10] - The company anticipates organic revenue growth of 3%-4% for 2026, with a cautious outlook on China impacting overall guidance [22][23] - Management highlighted the importance of new product launches and regulatory approvals in driving future growth [30] Other Important Information - The company has made significant investments in innovation, deploying over $1.7 billion in 2025 to strengthen competitiveness [17] - The service business grew mid-single digits in 2025, with expectations for increased capture rates of service agreements due to new product launches [11] Q&A Session Summary Question: Can you provide more color on the 2% order growth and outlook for orders in 2026? - Management noted a robust order backdrop with a book-to-bill ratio of 1.06 times and a record backlog, indicating a solid setup for 2026 [27][28] Question: What is the current state of Flyrcado and its adoption? - Management reported positive feedback from clinicians regarding Flyrcado's image quality and convenience, with consistent delivery rates improving [31][32] Question: How should we think about the potential upside in EPS related to China? - Management took a cautious approach regarding China, anticipating a decline in 2026 but noting improvements in VBP win rates and a robust imaging funnel [40][41] Question: Can you elaborate on the timing of orders and sales for new products? - Management indicated that significant new product launches are on track, with expected contributions primarily in 2027, but some impact anticipated in 2026 [60][61] Question: What are the expectations for pricing in 2026? - Management indicated that while there are no significant price increases expected initially, new products may lead to higher pricing as they are introduced [77]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenue of $5.7 billion, representing a 4.8% organic growth year-over-year, exceeding expectations [13] - For the full year 2025, total revenue reached $20.6 billion, with organic growth of 3.5%, ahead of guidance [15] - Adjusted EBIT margin for Q4 was 16.7%, down 200 basis points due to tariff expenses and unfavorable mix [13] - Adjusted EPS for Q4 was $1.44, down 0.7%, but grew 11% when excluding tariff impacts [14] - Free cash flow for Q4 was $916 million, up $105 million year-over-year [15] Business Line Data and Key Metrics Changes - Pharmaceutical Diagnostics saw organic sales growth of 12.7%, driven by global growth in contrast media and pricing execution [19] - Imaging organic revenue grew 5.3% in Q4, with strong performance in EMEA and the US, particularly in nuclear medicine [17] - Advanced Visualization Solutions reported a 4.2% organic revenue increase, supported by new product adoption [18] - Patient Care Solutions experienced a 1.1% decline in organic revenue due to a drop in life support solutions, but EBIT margin improved sequentially [19] Market Data and Key Metrics Changes - Demand in the U.S. and EMEA remained strong, with a record backlog of $21.8 billion, up $2 billion year-over-year [13] - The company secured multiple large agreements, including a significant collaboration with the University of Rochester Medical Center [4] - The capital equipment environment in the U.S. is robust, with many customers planning to increase investments in 2026 [3] Company Strategy and Development Direction - The company is focused on an innovation renaissance, emphasizing integrated solutions for complex and chronic diseases [3] - The strategic framework includes precision care, growth acceleration, and business optimization, with a strong emphasis on the Heartbeat business system to drive productivity and customer experience [10][11] - The planned acquisition of Intelerad is expected to enhance the company's cloud-first imaging ecosystem and drive recurring revenue [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering over $500 million in Flyrcado revenue by year-end 2028, with a long-term billion-dollar opportunity [9] - The outlook for 2026 includes organic revenue growth of 3%-4%, with a cautious approach to the Chinese market [22] - Management anticipates a decline in China for 2026 but sees potential upside if conditions improve [41] Other Important Information - The company deployed over $1.7 billion in innovation investment in 2025, prioritizing programs that strengthen competitiveness [17] - The service business grew mid-single digits in 2025, with expectations for increased capture rates of service agreements due to new product launches [10] Q&A Session Summary Question: Can you provide more color on the 2% order growth and outlook for orders in 2026? - Management noted a robust order backdrop with a book-to-bill ratio of 1.06 times and a record backlog, indicating a positive setup for 2026 [27][28] Question: What is the current state of Flyrcado and its adoption? - Management reported positive feedback from clinicians regarding Flyrcado's image quality and convenience, with consistent delivery rates improving [31][32] Question: How does the company view the situation in China and its impact on EPS? - Management took a cautious approach regarding China, anticipating a decline in 2026 but monitoring for potential upside as conditions evolve [40][41] Question: Can you elaborate on the assumptions for 2026 EPS guidance? - Management explained that the guidance reflects expected volume growth and cost initiatives, with a focus on maintaining investments in growth [44][48] Question: What is the status of the Intelerad acquisition? - The acquisition is expected to close in the first half of the year, enhancing the company's capabilities in cloud-enabled AI solutions [79][80]